Stefanie Alzate

627 total citations
7 papers, 83 citations indexed

About

Stefanie Alzate is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Stefanie Alzate has authored 7 papers receiving a total of 83 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 5 papers in Molecular Biology and 2 papers in Oncology. Recurrent topics in Stefanie Alzate's work include Multiple Myeloma Research and Treatments (7 papers), Cancer therapeutics and mechanisms (4 papers) and Protein Degradation and Inhibitors (4 papers). Stefanie Alzate is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Cancer therapeutics and mechanisms (4 papers) and Protein Degradation and Inhibitors (4 papers). Stefanie Alzate collaborates with scholars based in France, United States and Norway. Stefanie Alzate's co-authors include Cyrille Touzeau, Thierry Façon, Jonathan L. Kaufman, Shaji Kumar, Jeremy A. Ross, Philippe Moreau, Ravi Vij, Martin Dunbar, Joseph Mıkhael and Paulo Maciag and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Lymphoma Myeloma & Leukemia.

In The Last Decade

Stefanie Alzate

7 papers receiving 83 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stefanie Alzate France 6 61 60 30 24 12 7 83
Elżbieta Patkowska Poland 7 44 0.7× 90 1.5× 36 1.2× 17 0.7× 22 1.8× 22 114
Jarosław Czyż Poland 6 33 0.5× 45 0.8× 20 0.7× 23 1.0× 12 1.0× 17 85
Kalyan Nadiminti United States 6 65 1.1× 68 1.1× 18 0.6× 24 1.0× 6 0.5× 24 115
Stefano Ulisciani Italy 4 40 0.7× 71 1.2× 45 1.5× 10 0.4× 5 0.4× 6 96
Harald Polzer Germany 6 83 1.4× 111 1.9× 39 1.3× 18 0.8× 13 1.1× 9 141
Evan Massi United States 3 75 1.2× 116 1.9× 40 1.3× 12 0.5× 12 1.0× 3 134
Emil Hermansen Denmark 5 94 1.5× 71 1.2× 11 0.4× 36 1.5× 6 0.5× 13 122
J.-Th. Fischer Germany 5 52 0.9× 72 1.2× 17 0.6× 28 1.2× 16 1.3× 9 101
Konstanze Doehner Germany 4 68 1.1× 41 0.7× 13 0.4× 18 0.8× 9 0.8× 14 101
Christoph Rummelt Germany 5 35 0.6× 50 0.8× 20 0.7× 16 0.7× 11 0.9× 7 73

Countries citing papers authored by Stefanie Alzate

Since Specialization
Citations

This map shows the geographic impact of Stefanie Alzate's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefanie Alzate with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefanie Alzate more than expected).

Fields of papers citing papers by Stefanie Alzate

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefanie Alzate. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefanie Alzate. The network helps show where Stefanie Alzate may publish in the future.

Co-authorship network of co-authors of Stefanie Alzate

This figure shows the co-authorship network connecting the top 25 collaborators of Stefanie Alzate. A scholar is included among the top collaborators of Stefanie Alzate based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefanie Alzate. Stefanie Alzate is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Kaufman, Jonathan L., Cristina Gasparetto, Fredrik Schjesvold, et al.. (2019). Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma. Blood. 134(Supplement_1). 926–926. 16 indexed citations
2.
Kaufman, Jonathan L., Cristina Gasparetto, Joseph Mıkhael, et al.. (2017). Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma. Blood. 130. 3131–3131. 12 indexed citations
3.
Kumar, Shaji, Ravi Vij, Jonathan L. Kaufman, et al.. (2016). Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 34(15_suppl). 8032–8032. 5 indexed citations
4.
Kumar, Shaji, Ravi Vij, Jonathan L. Kaufman, et al.. (2016). Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study. Blood. 128(22). 488–488. 30 indexed citations
5.
Kumar, Shaji, Ravi Vij, Jonathan L. Kaufman, et al.. (2015). Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results. Blood. 126(23). 4219–4219. 13 indexed citations
6.
Kumar, Shaji, Ravi Vij, Jonathan L. Kaufman, et al.. (2015). Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).. Journal of Clinical Oncology. 33(15_suppl). 8576–8576. 6 indexed citations
7.
Kumar, Shaji, Ravi Vij, Jonathan L. Kaufman, et al.. (2015). Phase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM). Clinical Lymphoma Myeloma & Leukemia. 15. e81–e82. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elżbieta Patkowska Breakdown of academic impact, for papers by Jarosław Czyż Breakdown of academic impact, for papers by Kalyan Nadiminti Breakdown of academic impact, for papers by Stefano Ulisciani Breakdown of academic impact, for papers by Harald Polzer Breakdown of academic impact, for papers by Evan Massi Breakdown of academic impact, for papers by Emil Hermansen Breakdown of academic impact, for papers by J.-Th. Fischer Breakdown of academic impact, for papers by Konstanze Doehner Breakdown of academic impact, for papers by Christoph Rummelt
Rankless by CCL
2026